Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

357
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
357
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auricularia auricula Polysaccharide Extracted Under Ultrahigh Pressure: Structural Characterization and Immunomodulatory Mechanism.

Journal of food science·2026
Same author

Placental toxic metal concentrations and preterm birth: Modification by social stressors.

Reproductive toxicology (Elmsford, N.Y.)·2026
Same author

Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.

Materials today. Bio·2026
Same author

A dihydrofuro[2,3-b] benzofuran derivative alleviates lipopolysaccharide induced acute lung injury <i>via</i> suppressing MAPK signaling.

Frontiers in pharmacology·2026
Same author

Exploring the CeRNA landscape in plants: advances, methods, and challenges.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2026
Same author

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.

American journal of physiology. Lung cellular and molecular physiology·2026

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.8K

Establishment of reference standards in biosimilar studies.

Aijing Zhang, Jung-Ying Tzeng, Shein-Chung Chow

    Gabi Journal
    |April 16, 2014
    PubMed
    Summary

    Establishing a reliable reference standard is crucial for biosimilar product assessment when innovative drug data is limited. This study introduces a biosimilarity index approach using a reference-replicated study to create this essential standard.

    Keywords:
    Biosimilaritybiosimilarity indexhighly similarreference standardsreference-replicated study

    More Related Videos

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    17.0K
    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
    06:37

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

    Published on: September 15, 2023

    1.5K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
    04:50

    Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

    Published on: August 4, 2023

    1.8K
    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    17.0K
    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
    06:37

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

    Published on: September 15, 2023

    1.5K

    Area of Science:

    • Biopharmaceutical sciences
    • Biotechnology
    • Regulatory science

    Background:

    • Innovative biological products face patent expiration, leading to biosimilar development.
    • Limited availability of innovative product data complicates biosimilarity assessments.
    • A robust reference standard is essential for accurate biosimilar evaluation.

    Purpose of the Study:

    • To establish a reliable reference standard for biosimilarity assessment.
    • To address the challenge of missing data for innovative (reference) products.
    • To provide a method for comparing biosimilar products to their reference counterparts.

    Main Methods:

    • The study employed a biosimilarity index approach.
    • A reference-replicated (R-R) study design was utilized.
    • The reference product was compared against itself under diverse conditions to establish the standard.

    Main Results:

    • A method for establishing a reference standard was successfully developed.
    • The biosimilarity index approach, using R-R studies, proved effective.
    • The established reference standard can be applied to future biosimilar studies.

    Conclusions:

    • The proposed reference standard is vital for accurate biosimilarity assessment.
    • The biosimilarity index and R-R study offer a practical solution for data-limited scenarios.
    • This approach enhances the regulatory evaluation of biosimilar products.